From East to West: A Japanese Pharma perspective on establishing a global research capability

Drug Discovery Today

Volumn 14, Issue 11-12, 2009, Pages 611-617

  Takatani, Muneo ^a   Kenny, Barry ^b   Hird, Nick ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

^b Takeda Cambridge Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; APTAMER; CANDESARTAN; LANSOPRAZOLE; LEUPRORELIN; PIOGLITAZONE; SMALL INTERFERING RNA;

DIABETES MELLITUS; DRUG DESIGN; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; GASTROESOPHAGEAL REFLUX; HYPERTENSION; JAPAN; PROSTATE CANCER; REVIEW;

ANIMALS; BIOMEDICAL RESEARCH; DRUG DISCOVERY; HUMANS; INTERNATIONAL COOPERATION; JAPAN; TECHNOLOGY, PHARMACEUTICAL;

EID: 67349278498     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2009.03.010     Document Type: Review

References (17)

1. Franz S. Pipeline problems are increasing the urge to merge. Nat. Rev. Drug Discov. 5 (2006) 977-979
2. Gershell L.J. A brief history of novel drug discovery technologies. Nat. Rev. Drug Discov. 2 (2003) 321-327
3. Chin-Dusting J., et al. Finding improved medicines: the role of academic-industrial collaboration. Nat. Rev. Drug Discov. 4 (2005) 891-897
4. Dean P. Building relationships between academia and the pharmaceutical industry. Drug Discov. Today 5 (2000) 377-378
5. Reaume A. Is corporate venture capital a prescription for success in the pharmaceutical industry?. J. Private Equity Fall (2003) 77-87
6. Seminara S.B., et al. The GPR54 gene as a regulator of puberty. New Engl. J. Med. 349 (2003) 1614-1627
7. Tralau-Stewart C.J., et al. Drug discovery: new models for industry-academic partnerships. Drug Discov. Today 14 (2009) 95-101
8. In the author's opinion the recent film "Lost in Translation" wonderfully captures the culture difference (http://www.lost-in-translation.com/)
9. Murtagh, N. (2005) The blue-eyed salaryman Profile Books, London ISBN: 9781861977892
10. Szepkouski B. Business Passport to Japan (2007), Stone Bridge Press, MA, USA. 9781933330471
11. Hodgson J.D., et al. Doing Business with the New Japan: Succeeding in America's Richest International Market (2007), Rowman & Littlefield, MD, USA. 9780742555334
12. Kubini H. Drug research: myths, hype and reality. Nat. Rev. Drug Discov. 2 (2003) 665-668
13. Gribbon P., and Sewing A. High-throughput drug discovery: what can we expect from HTS?. Drug Discov. Today 10 (2005) 17-22
14. Bleicher K.H. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov. 2 (2003) 369-378
15. Houston J., et al. Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006. Drug Discov. Today 13 (2008) 44-51
16. Schmid E., and Smith D. R&D technology investments: misguided and expensive or a better way to discover medicines?. Drug Discov. Today. 11 (2006) 775-784
17. Kola I., and Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 3 (2004) 711-715